Portfolio company
Biophta
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
4 investors
Sectors
About
This company develops self-administered ocular inserts providing seven-day continuous drug release for patients with glaucoma and macular oedema.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
INEYE Therapeutics
This company develops ocular drug delivery inserts to treat chronic eye conditions such as dry eye and glaucoma for patients.
Perfuse Therapeutics
The company develops sustained-release intravitreal therapies to treat ischemia-driven ocular diseases for patients with conditions like glaucoma and diabetic retinopathy.
Rheon Medical SA
This company develops adjustable drainage devices and ocular implants for the surgical treatment of glaucoma in patients.
Envisia
This clinical-stage biotechnology company develops extended-release ocular therapies for patients with glaucoma and other eye disorders.
Tavo Biotherapeutics
The company develops topical and injectable treatments for patients with glaucoma and retinal diseases.
SpyGlass Pharma, Inc
The company develops an intraocular lens drug delivery system for patients with glaucoma to provide long-term medication during cataract surgery.
Bionode
The company develops wearable neuro-modulation devices and gold-trace contact lenses to treat and prevent elevated intraocular pressure in patients with glaucoma.
Oculis
This biopharmaceutical company develops topical therapies and delivery systems to treat neuro-ophthalmic and ophthalmic diseases for patients with unmet medical needs.